Cassava Sciences, Inc., a clinical-stage biotechnology company headquartered in Austin, Texas, has been actively engaged in the development of treatments for neurodegenerative diseases, with a particular focus on Alzheimer’s disease. As a key player in the health care sector, specifically within the pharmaceuticals industry, Cassava Sciences operates under the primary exchange of Nasdaq, trading in USD.
As of November 10, 2025, the company’s close price stood at $3.11. This figure reflects a significant fluctuation over the past year, with the 52-week high reaching $33.98 on November 20, 2024, and a 52-week low of $1.15 recorded on April 9, 2025. These variations highlight the volatility in the company’s stock performance, which is not uncommon in the biotechnology sector, particularly for companies in the clinical stages of drug development.
Cassava Sciences boasts a market capitalization of approximately $147.83 million, indicating its valuation within the market. The company’s price-to-earnings (P/E) ratio is currently at -1.19, a metric that often reflects the challenges faced by companies that are not yet profitable, which is typical for firms in the early stages of bringing new therapies to market.
Founded in 2000, Cassava Sciences went public on the Nasdaq stock exchange on July 14 of the same year. Since then, the company has dedicated its efforts to addressing the pressing need for effective treatments for neurodegenerative conditions, which affect millions of individuals worldwide. By focusing on innovative therapeutic approaches, Cassava Sciences aims to make significant contributions to the field of neurology and improve patient outcomes.
The company’s operations are primarily based in the United States, where it serves its clients and continues to advance its research and development initiatives. For those interested in learning more about Cassava Sciences and its endeavors, further information is available on their official website at www.cassavasciences.com .
In summary, Cassava Sciences, Inc. remains committed to its mission of developing groundbreaking treatments for neurodegenerative diseases, navigating the complexities of the biotechnology landscape while striving to achieve its scientific and commercial objectives.
